Grant: Doctoral Research Award: Canada Graduate Scholarships
McMaster University
$105,000.00
Development of novel in silico tools to predict pathogenicity of rare variants using post-translational modification data
FY 2019-20
Summary
All humans have mutations that alter the product of their genes. In healthy individuals, these mutations are benign. In individuals with genetic disorders, such as familial hypercholesterolemia, one or more of these mutations are often the cause of their disease. For clinicians, identifying the disease-causing mutation is akin to finding a "needle-in-a-haystack". It is impossible to validate each mutation in a laboratory, so computational tools must be used to prioritize the list of suspected mutations. However, existing methods are too inaccurate for use in clinical settings. Post-translational modifications on proteins are an important source of regulation in cells. One such modification is the cleavage of proteins by protease enzymes based on recognition of patterns of amino acids on the target. This cleavage is necessary for proper functioning of the target protein. Therefore, it would be expected that a mutation that removes an existing protease cleavage site results in an inactive protein, while a mutation that inappropriately induces a protease cleavage site results in a truncated non-functional protein. Despite their regulatory importance, there are no computational tools that incorporate these enzymes into their predictions of disease-causing versus benign for mutations. Therefore, our project seeks to develop a novel tool that leverages machine learning and databases of known protease cleavage sites in humans to improve prediction of disease-causing mutations. Ultimately, this project will create a catalogue of human mutations involving altered protease sites. In the short-term, this will benefit clinicians and their patients with genetic disorders. In the long-term, it will improve understanding of the role of proteases in disease with potential for new drug therapies. Also, it will generally improve identification of disease-causing mutations, which is a precursor to emerging therapies in precision medicine, like CRISPR gene editing.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
416752
Name
Mohammadi-Shemirani Pedrum
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development of novel in silico tools to predict pathogenicity of rare variants using post-translational modification data
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Exome Sequencing; Genetic Disorders; Genetic Epidemiology; Genomics; Proteomics
Abstract
All humans have mutations that alter the product of their genes. In healthy individuals, these mutations are benign. In individuals with genetic disorders, such as familial hypercholesterolemia, one or more of these mutations are often the cause of their disease. For clinicians, identifying the disease-causing mutation is akin to finding a "needle-in-a-haystack". It is impossible to validate each mutation in a laboratory, so computational tools must be used to prioritize the list of suspected mutations. However, existing methods are too inaccurate for use in clinical settings. Post-translational modifications on proteins are an important source of regulation in cells. One such modification is the cleavage of proteins by protease enzymes based on recognition of patterns of amino acids on the target. This cleavage is necessary for proper functioning of the target protein. Therefore, it would be expected that a mutation that removes an existing protease cleavage site results in an inactive protein, while a mutation that inappropriately induces a protease cleavage site results in a truncated non-functional protein. Despite their regulatory importance, there are no computational tools that incorporate these enzymes into their predictions of disease-causing versus benign for mutations. Therefore, our project seeks to develop a novel tool that leverages machine learning and databases of known protease cleavage sites in humans to improve prediction of disease-causing mutations. Ultimately, this project will create a catalogue of human mutations involving altered protease sites. In the short-term, this will benefit clinicians and their patients with genetic disorders. In the long-term, it will improve understanding of the role of proteases in disease with potential for new drug therapies. Also, it will generally improve identification of disease-causing mutations, which is a precursor to emerging therapies in precision medicine, like CRISPR gene editing.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mohammadi-Shemirani, Pedrum
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~